Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its drug ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is an August 25, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after disclosing regulatory scrutiny, the stock price dropped by $4.18 per share, or 7.13%, closing at $54.43 [6]. - A second patient death reported on June 15, 2025, led to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [8]. - Following an FDA Safety Communication on June 24, 2025, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [9]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [3].

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. concerning allegations of securities fraud and unlawful business practices related to its drug ELEVIDYS [1][2]. Group 1: Lawsuit Details - The lawsuit involves claims that Sarepta and certain officers/directors engaged in securities fraud or other unlawful practices [2]. - Investors who purchased Sarepta securities during the Class Period have until August 25, 2025, to request appointment as Lead Plaintiff [2]. Group 2: Impact of ELEVIDYS - On March 18, 2025, Sarepta reported the death of a patient with Duchenne muscular dystrophy after treatment with ELEVIDYS, leading to a stock price drop of $27.81 (27.44%) to $73.54 [4]. - Following a request from EU authorities for a review of the death, Sarepta halted recruitment and dosing in some clinical studies, resulting in a further stock decline of $4.18 (7.13%) to $54.43 on April 4, 2025 [5]. - A second fatality from acute liver failure was reported on June 15, 2025, prompting Sarepta to halt its clinical trial and suspend distribution of ELEVIDYS, causing a significant stock drop of $15.24 (42.12%) to $20.94 [6]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks associated with ELEVIDYS, leading to a stock price decrease of $1.52 (8.01%) to $17.46 [7].

Core Points - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the company's gene therapy product, ELEVIDYS [1] - The class period for the lawsuit is from June 22, 2023, to June 24, 2025, during which significant safety risks and adverse events associated with ELEVIDYS were allegedly not disclosed [1] - Shareholders are encouraged to register for participation in the class action by the deadline of August 25, 2025, to potentially be appointed as lead plaintiffs [1] Allegations - The complaint alleges that Sarepta Therapeutics made materially false and misleading statements regarding the safety of ELEVIDYS, a gene therapy for Duchenne muscular dystrophy [1] - Specific allegations include failure to disclose significant safety risks, inadequate trial protocols to detect severe side effects, and the potential halting of recruitment and dosing in trials due to adverse events [1] - The misleading statements are said to have artificially inflated the company's stock value, leading to investor losses [2] Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are advised to register for the class action to receive updates and monitor the case [1] - There is no cost or obligation for shareholders to participate in the case [1]

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of its gene therapy ELEVIDYS for Duchenne, which posed significant risks to patients [2] - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, leading to potential halting of recruitment and dosing in trials, increased regulatory scrutiny, and risks to therapy approvals [2] - The defendants are accused of materially misleading investors and lacking a reasonable basis for their positive statements about ELEVIDYS [2] Group 2: Next Steps for Investors - Investors who suffered losses in Sarepta during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4] - The firm has over 70 employees and extensive expertise in complex securities litigation [4]

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The complaint alleges that Sarepta made false statements regarding the safety of its gene therapy ELEVIDYS for Duchenne, claiming it posed significant safety risks to patients [2] - It is claimed that the trial protocols for ELEVIDYS failed to detect severe side effects, leading to potential halting of recruitment and dosing in trials, attracting regulatory scrutiny [2] - The lawsuit asserts that the severity of adverse events from ELEVIDYS treatment misled investors and lacked a reasonable basis for positive statements made by the company [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on August 25, 2025 [1] Group 1: Class Action Details - Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Rosen Law Firm has been recognized for its performance in securities class action settlements, being ranked No. 1 in 2017 and consistently in the top 4 since 2013 [4] Group 3: Case Specifics - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [5] - Key issues raised include significant safety risks associated with ELEVIDYS, failure to detect severe side effects in trials, and the potential for regulatory scrutiny due to adverse events [5] - The lawsuit claims that these misrepresentations led to investor damages when the true information became public [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. Specific allegations include: - Significant safety risks associated with ELEVIDYS were not disclosed [3]. - Trial protocols failed to identify severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action. The deadline for seeking lead plaintiff status is August 25, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud. The firm aims to ensure companies engage in responsible business practices [5].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects, and the potential for halting clinical trials due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the specified class period [1][2]. Group 1: Allegations Against Sarepta - The lawsuit claims that Sarepta made false or misleading statements about the safety risks associated with its gene therapy treatment, ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to regulatory scrutiny and halt recruitment and dosing in trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have been downplayed, resulting in materially misleading statements from the defendants [2]. Group 2: Legal Process and Participation - Investors in Sarepta have until August 25, 2025, to seek appointment as lead plaintiffs in the class action, representing the interests of all class members [3]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case, who will select counsel to represent the class [3]. - Investors can choose to participate actively or remain absent from the proceedings without affecting their ability to share in any recovery [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering significant amounts for victims of corporate misconduct [4]. - The firm emphasizes its commitment to protecting investors and consumers from fraud and negligence [4].